"We are very pleased to have received strong support from top-tier and sophisticated biopharmaceutical investors," said Mr. Smith. "These funds will enable us to combine commercially validated particle technologies with the drug delivery, formulation, and product development know-how of the Pearl team to create differentiated products with the potential to broadly and effectively address serious respiratory conditions."
"Pearl Therapeutics incorporates a founding management team with a strong track record of success and expertise in pulmonary drug development including the scale up and commercialization of new products based on proprietary particle technologies. We believe Pearl's products offer the potential for improved treatment of a wider population of patients with chronic respiratory disease," said Dr. Young, executive chairman of the Company, on behalf of the company's investors. "Based on my experience in drug delivery and product development, I am excited to have the opportunity to work with this team and company."
"Adrian and Sarvajna have expert backgrounds in developing pulmonary products and we're pleased that our former colleagues will be exploring new applications with our suite of proven particle technologies," Mr. Elam said.
About Pearl Therapeutics, Inc.
Pearl Therapeutics is focused on developing a pipeline of novel and
superior products for chronic respiratory disorders, providing patients
|SOURCE Pearl Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved